PKTX · Protokinetix, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $24.2K | $24.4K | $33.8K | - | $21.0K | $21.0K | $36.6K | - | $21.3K | $32.0K |
| SG&A | $16.2K | $14.1K | $14.7K | - | $16.3K | $13.2K | $14.1K | - | $16.5K | $35.7K |
| Total Operating Expenses | $84.9K | $91.1K | $97.7K | - | $84.6K | $85.1K | $92.0K | - | $80.4K | $115.6K |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($84.9K) | ($91.1K) | ($97.7K) | - | ($84.6K) | ($85.1K) | ($92.0K) | - | ($80.4K) | ($115.6K) |
| EPS - Basic | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | ($0.01) | - | $0.00 | ($0.01) |
| EPS - Diluted | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | ($0.01) | - | ($0.01) | ($0.01) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $607 | $112 | $49.5K | - | $5.7K | $2.2K | $2.8K | $20.4K | $12.4K | $18.7K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $227.2K | $149.1K | $152.2K | $124.0K | $87.7K | $58.8K | $67.6K | $44.7K | $12.6K | $13.3K |
| Current Assets | - | - | - | - | $6.7K | $3.3K | $3.9K | $21.5K | $13.4K | $19.7K |
| Total Assets | $477.6K | $474.4K | $528.6K | $466.1K | $479.3K | $473.5K | $461.4K | $480.6K | $450.9K | $467.0K |
| Current Liabilities | $227.2K | $149.1K | $152.2K | $124.0K | $87.7K | $58.8K | $67.6K | $44.7K | $12.6K | $13.3K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $250.4K | $325.3K | $376.4K | $342.1K | $391.5K | $414.8K | $393.8K | $435.9K | $438.3K | $453.7K |
| Retained Earnings | ($48.50M) | ($48.42M) | ($48.33M) | ($48.23M) | ($48.13M) | ($48.04M) | ($47.96M) | ($47.86M) | ($47.75M) | ($47.67M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($52.0K) | - | - | - | ($57.8K) | - | - | - |
| Investing Cash Flow | - | - | ($25.9K) | - | - | - | ($9.7K) | - | - | - |
| Financing Cash Flow | - | - | $132.0K | - | - | - | $50.0K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -17.8% | -19.2% | -18.5% | - | -17.6% | -18.0% | -19.9% | - | -17.8% | -24.7% |
| Return on equity | -33.9% | -28.0% | -26.0% | - | -21.6% | -20.5% | -23.4% | - | -18.3% | -25.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | - | - | - | 0.08 | 0.06 | 0.06 | 0.48 | 1.07 | 1.49 |
| Quick ratio | - | - | - | - | 0.08 | 0.06 | 0.06 | 0.48 | 1.07 | 1.49 |
| Cash ratio | 0.00 | 0.00 | 0.33 | - | 0.06 | 0.04 | 0.04 | 0.46 | 0.99 | 1.41 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.91 | 1.46 | 1.40 | 1.36 | 1.22 | 1.14 | 1.17 | 1.10 | 1.03 | 1.03 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 8.6x | 9.5x | 12.0x | - | 10.0x | 8.5x | 16.7x | - | 18.4x | 18.0x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | -0.4% | -7.0% | -6.2% | - | -5.2% | 26.4% | 14.0% | - | 78.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -36.0% | -21.6% | -4.4% | -21.5% | -10.7% | -8.6% | -0.1% | 3.4% | 17.0% | 20.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ProtoKinetix against the 5 most active filers in the same SIC group.